News articles about Pfizer (NYSE:PFE) have been trending somewhat positive on Sunday, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pfizer earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.9860210332082 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Credit Suisse Group Analysts Give Pfizer (PFE) a $39.00 Price Target (americanbankingnews.com)
- Pfizer’s Epilepsy Drug Lyrica Succeeds in Pediatric Study (zacks.com)
- Buy Pfizer; target of Rs 3000: ICICI Direct (moneycontrol.com)
- Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug (finance.yahoo.com)
- Eli Lilly’s Valuation on May 17 (finance.yahoo.com)
Several research analysts recently weighed in on PFE shares. Morningstar set a $38.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, January 30th. Credit Suisse Group reiterated a “neutral” rating and set a $39.00 price target on shares of Pfizer in a research report on Friday. Barclays cut Pfizer from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $41.00 to $38.00 in a research report on Thursday, April 5th. UBS set a $42.00 price target on Pfizer and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a research report on Wednesday, January 24th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $40.08.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The business had revenue of $12.91 billion during the quarter, compared to analysts’ expectations of $13.14 billion. During the same period in the previous year, the business earned $0.69 earnings per share. The business’s revenue was up 1.0% compared to the same quarter last year. equities research analysts anticipate that Pfizer will post 2.95 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, May 11th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.82%. The ex-dividend date is Thursday, May 10th. Pfizer’s payout ratio is 51.32%.
In related news, insider Charles H. Hill sold 42,393 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the sale, the insider now owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Insiders have sold 380,349 shares of company stock valued at $13,829,340 over the last quarter. 0.06% of the stock is owned by company insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.